Literature DB >> 24461907

Phenotypic spectrum of eleven patients and five novel MTFMT mutations identified by exome sequencing and candidate gene screening.

Tobias B Haack1, Matteo Gorza2, Katharina Danhauser1, Johannes A Mayr3, Birgit Haberberger4, Thomas Wieland2, Laura Kremer2, Valentina Strecker5, Elisabeth Graf2, Yasin Memari6, Uwe Ahting4, Robert Kopajtich2, Saskia B Wortmann7, Richard J Rodenburg7, Urania Kotzaeridou8, Georg F Hoffmann8, Wolfgang Sperl3, Ilka Wittig5, Ekkehard Wilichowski9, Gudrun Schottmann10, Markus Schuelke10, Barbara Plecko11, Ulrich Stephani12, Tim M Strom1, Thomas Meitinger1, Holger Prokisch1, Peter Freisinger13.   

Abstract

Defects of mitochondrial oxidative phosphorylation (OXPHOS) are associated with a wide range of clinical phenotypes and time courses. Combined OXPHOS deficiencies are mainly caused by mutations of nuclear genes that are involved in mitochondrial protein translation. Due to their genetic heterogeneity it is almost impossible to diagnose OXPHOS patients on clinical grounds alone. Hence next generation sequencing (NGS) provides a distinct advantage over candidate gene sequencing to discover the underlying genetic defect in a timely manner. One recent example is the identification of mutations in MTFMT that impair mitochondrial protein translation through decreased formylation of Met-tRNA(Met). Here we report the results of a combined exome sequencing and candidate gene screening study. We identified nine additional MTFMT patients from eight families who were affected with Leigh encephalopathy or white matter disease, microcephaly, mental retardation, ataxia, and muscular hypotonia. In four patients, the causal mutations were identified by exome sequencing followed by stringent bioinformatic filtering. In one index case, exome sequencing identified a single heterozygous mutation leading to Sanger sequencing which identified a second mutation in the non-covered first exon. High-resolution melting curve-based MTFMT screening in 350 OXPHPOS patients identified pathogenic mutations in another three index cases. Mutations in one of them were not covered by previous exome sequencing. All novel mutations predict a loss-of-function or result in a severe decrease in MTFMT protein in patients' fibroblasts accompanied by reduced steady-state levels of complex I and IV subunits. Being present in 11 out of 13 index cases the c.626C>T mutation is one of the most frequent disease alleles underlying OXPHOS disorders. We provide detailed clinical descriptions on eleven MTFMT patients and review five previously reported cases.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Exome sequencing; Leigh syndrome; MTFMT; Mitochondrial translation; OXPHOS deficiency

Mesh:

Substances:

Year:  2013        PMID: 24461907     DOI: 10.1016/j.ymgme.2013.12.010

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  40 in total

Review 1.  Movement disorders in mitochondrial disease.

Authors:  Roula Ghaoui; Carolyn M Sue
Journal:  J Neurol       Date:  2018-01-06       Impact factor: 4.849

Review 2.  Evolutionary conservation and expression of human RNA-binding proteins and their role in human genetic disease.

Authors:  Stefanie Gerstberger; Markus Hafner; Manuel Ascano; Thomas Tuschl
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

3.  Widening the Heterogeneity of Leigh Syndrome: Clinical, Biochemical, and Neuroradiologic Features in a Patient Harboring a NDUFA10 Mutation.

Authors:  Francesca Minoia; Marta Bertamino; Paolo Picco; Mariasavina Severino; Andrea Rossi; Chiara Fiorillo; Carlo Minetti; Claudia Nesti; Filippo Maria Santorelli; Maja Di Rocco
Journal:  JIMD Rep       Date:  2017-03-01

4.  Atypical Clinical Presentations of TAZ Mutations: An Underdiagnosed Cause of Growth Retardation?

Authors:  Charlotte Thiels; Martin Fleger; Martina Huemer; Richard J Rodenburg; Frederic M Vaz; Riekelt H Houtkooper; Tobias B Haack; Holger Prokisch; René G Feichtinger; Thomas Lücke; Johannes A Mayr; Saskia B Wortmann
Journal:  JIMD Rep       Date:  2016-01-03

5.  EARS2 mutations cause fatal neonatal lactic acidosis, recurrent hypoglycemia and agenesis of corpus callosum.

Authors:  Katharina Danhauser; Tobias B Haack; Bader Alhaddad; Marlen Melcher; Annette Seibt; Tim M Strom; Thomas Meitinger; Dirk Klee; Ertan Mayatepek; Holger Prokisch; Felix Distelmaier
Journal:  Metab Brain Dis       Date:  2016-01-16       Impact factor: 3.584

6.  An N-terminal formyl methionine on COX 1 is required for the assembly of cytochrome c oxidase.

Authors:  Reetta Hinttala; Florin Sasarman; Tamiko Nishimura; Hana Antonicka; Catherine Brunel-Guitton; Jeremy Schwartzentruber; Somayyeh Fahiminiya; Jacek Majewski; Denis Faubert; Elsebet Ostergaard; Jan A Smeitink; Eric A Shoubridge
Journal:  Hum Mol Genet       Date:  2015-04-24       Impact factor: 6.150

7.  Genetic cause and prevalence of hydroxyprolinemia.

Authors:  Christian Staufner; Tobias B Haack; Patrik Feyh; Gwendolyn Gramer; Deepthi Ediga Raga; Caterina Terrile; Sven Sauer; Jürgen G Okun; Junmin Fang-Hoffmann; Ertan Mayatepek; Holger Prokisch; Georg F Hoffmann; Stefan Kölker
Journal:  J Inherit Metab Dis       Date:  2016-05-02       Impact factor: 4.982

8.  Neonatal encephalocardiomyopathy caused by mutations in VARS2.

Authors:  Fabian Baertling; Bader Alhaddad; Annette Seibt; Sonja Budaeus; Thomas Meitinger; Tim M Strom; Ertan Mayatepek; Jörg Schaper; Holger Prokisch; Tobias B Haack; Felix Distelmaier
Journal:  Metab Brain Dis       Date:  2016-08-08       Impact factor: 3.584

9.  Cre recombinase activity is inhibited in vivo but not ex vivo by a mutation in the asymmetric spacer region of the distal loxP site.

Authors:  Tania Arguello; Carlos T Moraes
Journal:  Genesis       Date:  2015-09-18       Impact factor: 2.487

10.  Mitochondrial methionyl N-formylation affects steady-state levels of oxidative phosphorylation complexes and their organization into supercomplexes.

Authors:  Tania Arguello; Caroline Köhrer; Uttam L RajBhandary; Carlos T Moraes
Journal:  J Biol Chem       Date:  2018-08-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.